Skip to main content
Have a personal or library account? Click to login
Neoadjuvant chemotherapy in 13 patients with locally advanced poorly differentiated thyroid carcinoma based on Turin proposal - a single institution experience Cover

Neoadjuvant chemotherapy in 13 patients with locally advanced poorly differentiated thyroid carcinoma based on Turin proposal - a single institution experience

Radiology and Oncology
Volume 49 (2015): Issue 3 (September 2015)
By: ,  ,   and    
Open Access
|Aug 2015
References

References

  1. 1. Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas.1983;1849-55.
    Open DOISearch in Google Scholar
  2. 2. Sobrinho-Simões M, Albores-Saavedra J, Tallini G. Poorly differentiated carcinoma. In: DeLellis RA, Lloyd RV, Heitz U, Eng C, editors,Lyon: World Health Organization, IARC Press, France; 2004. p. 73-6.
    Search in Google Scholar
  3. 3. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach.2007;1256-64.
    Open DOISearch in Google Scholar
  4. 4. Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer.2006;119-28.
    Open DOISearch in Google Scholar
  5. 5. Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression.2010;1269-78.
    Open DOISearch in Google Scholar
  6. 6. Ito Y, Hirokawa M, Fukushima M, Inoue H, Yabuta T, Uruno T, et al. Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan.2008;1535-43.
    Open DOISearch in Google Scholar
  7. 7. Sanders EM Jr, LiVolsi VA, Brierley J, Shin J, Randolph GW. An evidence-based review of poorly differentiated thyroid cancer.2007;934-45.
    Open DOISearch in Google Scholar
  8. 8. Auersperg M, Us-Krasovec M, Petric G, Pogacnik A, Besic N. Results of combined modality treatment in poorly-differentiated and anaplastic thyroid carcinoma.1990;267-70.
    Search in Google Scholar
  9. 9. Ibrahimpasic T, Ghossein R, Carlson DL, Chernichenko N, Nixon I, Palmer FL, et al. Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986-2009 Memorial Sloan-Kettering Cancer Center experience.2013;997-1002.
    Open DOISearch in Google Scholar
  10. 10. Lai HW, Lee CH, Chen JY, Tseng LM, Yang AH. Insular thyroid carcinoma: collective analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation therapy.2006;715-22.
    Open DOISearch in Google Scholar
  11. 11. Justin EP, Seabold JE, Robinson RA, Walker WP, Gurll NJ, Hawes DR. Insular carcinoma: a distinct thyroid carcinoma with associated iodine-131 localization.1991;1358-63.
    Search in Google Scholar
  12. 12. Besic N, Auersperg M, Dremelj M, Vidergar-Kralj B, Gazic B. Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma.2013;178-84.
    Open DOISearch in Google Scholar
  13. 13. Besic N, Auersperg M, Gazic B, Dremelj M, Zagar I. Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or Hürthle cell thyroid carcinoma: a phase 2 study.2012;131-7.
    Open DOISearch in Google Scholar
  14. 14. Sobin LH, Gospodarowitz MK, Witekind C. Thyroid gland (ICD-O C73). In: Sobin LH, Gospodarowitz MK, Witekind C, editors.7th edition. New York: Wiley Blackwell; 2009. p. 58-62.
    Open DOISearch in Google Scholar
  15. 15. Dobrenic M, Huic D, Zuvic M, Grosev D, Petrovic R, Samardzic T. Usefulness of low iodine diet in managing patients with differentiated thyroid cancer - initial results.2011;189-95.
    Open DOISearch in Google Scholar
  16. 16. Auersperg M, Us-Krasovec M, Pogacnik A, Hocevar M, Novak B, Besic N, et al. Induction chemotherapy in primarily inoperable differentiated thyroid carcinomas.1993;187-91.
    Search in Google Scholar
  17. 17. Zager V, Cemazar M, Hreljac I, Lah TT, Sersa G, Filipic M. Development of human cell biosensor system for genotoxicity detection based on DNA damage-induced gene expression.2010;42-51.
    Open DOISearch in Google Scholar
  18. 18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).2009;: 228-47.
    Open DOISearch in Google Scholar
  19. 19. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly-differentiated thyroid cancer.2002;4160-5.
    Open DOISearch in Google Scholar
  20. 20. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.2009;1167-214.
    Open DOISearch in Google Scholar
  21. 21. Marinko T, Dolenc J, Bilban-Jakopin C. Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer.2014;105-12.
    Open DOISearch in Google Scholar
  22. 22. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. The European Thyroid Cancer Taskforce: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.2006;787-803.
    Open DOISearch in Google Scholar
  23. 23. Jung TS, Kim TY, Kim KW, Oh YL, Park do J, Cho BY, et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma.2007;265-74.
    Open DOISearch in Google Scholar
  24. 24. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.2013;1277-83.
    Open DOISearch in Google Scholar
  25. 25. Liu M, Shen Y, Ruan M, Li M, Chen L. Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma.2014;1179-83.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.1515/raon-2015-0001 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 271 - 278
Submitted on: May 3, 2014
Accepted on: Oct 29, 2014
Published on: Aug 21, 2015
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
poorly differentiated thyroid carcinoma,
neoadjuvant,
chemotherapy,
survival,
pathology
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2015 Nikola Besic, Marta Dremelj, Andreja Schwartzbartl-Pevec, Barbara Gazic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 49 (2015): Issue 3 (September 2015)
Previous article
Next article